CDK8-Novel Therapeutic Opportunities
AbstractImprovements in cancer therapy frequently stem from the development of new small-molecule inhibitors, paralleled by the identification of biomarkers that can predict the treatment response. Recent evidence supports the idea that cyclin-dependent kinase 8 (CDK8) may represent a potential drug target for breast and prostate cancer, although no CDK8 inhibitors have entered the clinics. As the available inhibitors have been recently reviewed, we focus on the biological functions of CDK8 and provide an overview of the complexity of CDK8-dependent signaling throughout evolution and CDK8-dependent effects that may open novel treatment avenues. View Full-Text
Share & Cite This Article
Menzl, I.; Witalisz-Siepracka, A.; Sexl, V. CDK8-Novel Therapeutic Opportunities. Pharmaceuticals 2019, 12, 92.
Menzl I, Witalisz-Siepracka A, Sexl V. CDK8-Novel Therapeutic Opportunities. Pharmaceuticals. 2019; 12(2):92.Chicago/Turabian Style
Menzl, Ingeborg; Witalisz-Siepracka, Agnieszka; Sexl, Veronika. 2019. "CDK8-Novel Therapeutic Opportunities." Pharmaceuticals 12, no. 2: 92.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.